As I said before, it started out that companies were giving their drugs away for, in our case, a dollar a day. Then at some point they got to a comfort level that there wasn't as much diversion as they were fearing back into the developed world, to be honest. We could then license, so we started to license. Again, it was not the state-of-the-art technology but, let's say, the first generation of antiretroviral drugs that seemed to be having some success, and that's what created them. Aspen Pharmacare in South Africa, which we keep talking about, really was one of the great creations of that, because that really spurred their growth. In Brazil as well there were similar types of things, and in India as well with their companies.
That's how it began. From that, they built out to a point where you can see the Serum Institute of India today being able to have a voluntary licence to do the state-of-the-art AstraZeneca vaccine. You have to think that part of that came from the training that came from the HIV work; but on the other hand, as I keep saying, now that Serum has that training, they no longer want to just supply Africa.
Somebody mentioned earlier, and I think this is an important point to get in here, that Africans are paying more. The interesting thing about that is that the African countries are being charged more by the Serum Institute of India, not by AstraZeneca of London. That is something we need to keep in mind as we think through some of this as well.